TY  - JOUR
T1  - Bone Marrow, Peripheral Blood and Plasma for Quantitation of BCR-ABL Transcript in Chronic Myeloid Leukemia
A1  - Nguyen Truong Son
A1  - Hoang Thi Thuy Ha
A1  - Pham Van Loi
A1  - Le Hung Phong
A1  - Vy The Ha
A1  - Phan Cong Hoang
A1  - Nguyen Thi Lan Huong
A1  - Tran Thanh Tung
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2021
VL  - 12
IS  - 3
DO  - 10.51847/iDAK8dHPZe
SP  - 49
EP  - 53
N2  - Molecular diagnosis based on the quantitative monitoring of BCR-ABL transcript in Chronic Myeloid Leukemia (CML) using quantitative real-time PCR (qRT-PCR) has been performed in the bone marrow. Recently, the reliability of using the source of peripheral as well as plasma for BCR-ABL transcript quantitation has been questioned. We herein reported a study on 172 paired samples, partitioned into 3 groups, including before treatment (newly diagnosed CML), under 1 year, and more than 1 year after initiation of TKI therapy for BCR-ABL transcript quantitation as performed by qRT-PCR. Based on the results, quantitatively, we concluded that there was only agreement of BCR-ABL measurements among bone marrow, peripheral blood, and plasma in the group of the newly diagnosed CML patients based on the evaluation of %IS-NCN and the kappa-value. Our data suggested that the source sample of peripheral blood and plasma were suitable for the BCR-ABL transcripts quantitation for CML patients without undergoing TKI treatment. The plasma-based quantification assay was more sensitive in untreated patients compared to the bone marrow test.
UR  - https://pharmacophorejournal.com/article/bone-marrow-peripheral-blood-and-plasma-for-quantitation-of-bcr-abl-transcript-in-chronic-myeloid-l-iulvjjqkpp8sy7z
ER  -